Contact this trialFirst, we need to learn more about you.
Immunomodulatory agents
Mosunetuzumab + Lenalidomide for Follicular Lymphoma
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing mosunetuzumab + lenalidomide as a possible treatment for relapsed or refractory follicular lymphoma. Researchers will also compare the safety, efficacy, and immunogenicity of mosunetuzumab + len given intravenously versus subcutaneously.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service